These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 24451101)
1. Epidemiology of extended-spectrum β-lactamase, AmpC, and carbapenemase production in Proteus mirabilis. Datta P; Gupta V; Arora S; Garg S; Chander J Jpn J Infect Dis; 2014; 67(1):44-6. PubMed ID: 24451101 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of a modified double-disc synergy test for detection of extended spectrum beta-lactamases in AMPC beta-lactamase-producing proteus mirabilis. Khan MK; Thukral SS; Gaind R Indian J Med Microbiol; 2008; 26(1):58-61. PubMed ID: 18227600 [TBL] [Abstract][Full Text] [Related]
3. Prevalence of extended-spectrum β-lactamases, AmpC, and carbapenemases in Proteus mirabilis clinical isolates. Shaaban M; Elshaer SL; Abd El-Rahman OA BMC Microbiol; 2022 Oct; 22(1):247. PubMed ID: 36221063 [TBL] [Abstract][Full Text] [Related]
4. Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program. Wang JT; Chen PC; Chang SC; Shiau YR; Wang HY; Lai JF; Huang IW; Tan MC; Lauderdale TL; BMC Infect Dis; 2014 Sep; 14():486. PubMed ID: 25192738 [TBL] [Abstract][Full Text] [Related]
5. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria. Mohanty S; Gaind R; Ranjan R; Deb M J Infect Dev Ctries; 2009 Nov; 4(1):24-9. PubMed ID: 20130375 [TBL] [Abstract][Full Text] [Related]
6. [Evaluation of the MicroScan NegCombo panel Type 44 for detection of extended-spectrum beta-lactamase among clinical isolates of Escherichia coli, Klebsiella species, and Proteus mirabilis]. Ko SY; Chung JW; Song AJ; Yoon NS; Sung H; Kim MN Korean J Lab Med; 2009 Feb; 29(1):35-40. PubMed ID: 19262076 [TBL] [Abstract][Full Text] [Related]
7. Molecular drivers of emerging multidrug resistance in Proteus mirabilis clinical isolates from Algeria. Boudjemaa H; Allem R; Fonkou MDM; Zouagui S; Khennouchi NCEH; Kerkoud M J Glob Antimicrob Resist; 2019 Sep; 18():249-256. PubMed ID: 30797091 [TBL] [Abstract][Full Text] [Related]
8. Emergence of multidrug-resistant Proteus mirabilis in a long-term care facility in Croatia. Bedenić B; Firis N; Elveđi-Gašparović V; Krilanović M; Matanović K; Štimac I; Luxner J; Vraneš J; Meštrović T; Zarfel G; Grisold A Wien Klin Wochenschr; 2016 Jun; 128(11-12):404-13. PubMed ID: 27220339 [TBL] [Abstract][Full Text] [Related]
10. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases. Endimiani A; Luzzaro F; Brigante G; Perilli M; Lombardi G; Amicosante G; Rossolini GM; Toniolo A Antimicrob Agents Chemother; 2005 Jul; 49(7):2598-605. PubMed ID: 15980325 [TBL] [Abstract][Full Text] [Related]
11. Evolving beta-lactamase epidemiology in Enterobacteriaceae from Italian nationwide surveillance, October 2013: KPC-carbapenemase spreading among outpatients. Giani T; Antonelli A; Caltagirone M; Mauri C; Nicchi J; Arena F; Nucleo E; Bracco S; Pantosti A; ; Luzzaro F; Pagani L; Rossolini GM Euro Surveill; 2017 Aug; 22(31):. PubMed ID: 28797330 [TBL] [Abstract][Full Text] [Related]
12. Phenotypic Detection and Antibiogram of β-lactamase-producing Pal N; Hooja S; Sharma R; Maheshwari RK Ann Med Health Sci Res; 2016; 6(5):267-273. PubMed ID: 28503342 [TBL] [Abstract][Full Text] [Related]
13. [The presence of extended spectrum beta-lactamase, KPC-type carbapenemase and plasmid-mediated AmpC beta-lactamase in E.coli and K.pneumoniae strains isolated from blood cultures]. Baykal A; Cöplü N; Simşek H; Esen B; Gür D Mikrobiyol Bul; 2012 Apr; 46(2):159-69. PubMed ID: 22639305 [TBL] [Abstract][Full Text] [Related]
14. Regional outbreak of CTX-M-2 β-lactamase-producing Proteus mirabilis in Japan. Nakano R; Nakano A; Abe M; Inoue M; Okamoto R J Med Microbiol; 2012 Dec; 61(Pt 12):1727-1735. PubMed ID: 22935848 [TBL] [Abstract][Full Text] [Related]
15. Molecular epidemiology and antimicrobial susceptibility of AmpC- and/or extended-spectrum (ESBL) ß-lactamaseproducing Proteus spp. clinical isolates in Zenica-Doboj Canton, Bosnia and Herzegovina. Uzunović S; Ibrahimagić A; Hodžić D; Bedenić B Med Glas (Zenica); 2016 Aug; 13(2):103-12. PubMed ID: 27313108 [TBL] [Abstract][Full Text] [Related]
16. High prevalence and molecular characterization of extended-spectrum β-lactamase-producing Proteus mirabilis strains in southern Croatia. Tonkić M; Mohar B; Šiško-Kraljević K; Meško-Meglič K; Goić-Barišić I; Novak A; Kovačić A; Punda-Polić V J Med Microbiol; 2010 Oct; 59(Pt 10):1185-1190. PubMed ID: 20558587 [TBL] [Abstract][Full Text] [Related]
17. [Evaluation of the Phoenix automated microbiology system for detecting extended-spectrum beta-lactamase in Escherichia coli, Klebsiella species and Proteus mirabilis]. Lee KK; Kim ST; Hong KS; Huh HJ; Chae SL Korean J Lab Med; 2008 Jun; 28(3):185-90. PubMed ID: 18594169 [TBL] [Abstract][Full Text] [Related]
18. Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations. Luzzaro F; Perilli M; Amicosante G; Lombardi G; Belloni R; Zollo A; Bianchi C; Toniolo A Int J Antimicrob Agents; 2001 Feb; 17(2):131-5. PubMed ID: 11165117 [TBL] [Abstract][Full Text] [Related]
19. Prevalence and resistance patterns of extended-spectrum and AmpC β-lactamase in Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Salmonella serovar Stanley in a Korean tertiary hospital. Park SD; Uh Y; Lee G; Lim K; Kim JB; Jeong SH APMIS; 2010 Oct; 118(10):801-8. PubMed ID: 20854475 [TBL] [Abstract][Full Text] [Related]
20. Antimicrobial Susceptibility and Molecular Epidemiology of Lin MF; Liou ML; Kuo CH; Lin YY; Chen JY; Kuo HY Microb Drug Resist; 2019 Nov; 25(9):1338-1346. PubMed ID: 31295061 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]